Periodic Reporting for period 1 - TK-NEO (Personalized Cancer Immunotherapy through DNA-EP vaccines)

NEOMatrix, the new commercial name of TK-NEO, is an R&D initiative of Takis, a Biotechnology Company with a scientific group with more than 10 years of experience in drug discovery, including the validation of new targets for the treatment of chronic viral diseases and cancer...